Growth Opportunity Fulgent Oncology operates under Fulgent Genetics with CSI Laboratories and Inform Diagnostics, indicating potential cross-sell of advanced molecular diagnostics and cancer testing services to expand their portfolio within existing customers and channels.

Security Emphasis There have been multiple phishing and data breach events involving CSI Laboratories, highlighting a strong need for enhanced cybersecurity, compliance tooling, and staff training—a tangible sales entry point for security posture improvements and managed risk services.

Tech Stack Fit The current technology stack includes OneTrust, KnowBe4, Google Analytics, Google Tag Manager, and security headers, suggesting opportunities to streamline data privacy, user access governance, threat awareness training, and analytics optimization for enterprise reporting.

Pharma and Payer Alignment With a history of partnerships and lines of credit (Bank of America) and a revenue scale in the tens of millions, there are potential collaboration angles with payers, risk-sharing models, and capital financing for growth or technology upgrades in diagnostic services.

Expansion Readiness Recent leadership appointments and acquisitions, plus a nationwide reach across the United States and Caribbean, indicate they are in an expansion phase and may be receptive to services around scale operations, quality management, and supplier/vendor optimizations.